Top Tweets for #CheckMate9LA
#ASCO22 | Francesco Grossi about the amazing results of #CheckMate227 and #CheckMate9LA trials:
"From both studies we have confirmation of long survival with NIVO + IPI alone or in combination with chemotherapy." #NSCLC
オプジーボ・ヤーボイ・化学療法のCheckMate 9LA試験
⇒ https://t.co/WnDbG6mn60 #アメブロ @ameba_officialより
CheckMate 9LA試験についてYouTubeで解説しました。ぜひ最後までご視聴ください。
https://t.co/wApcX0m5RA
#ヤーボイ
#オプジーボ
#CheckMate9LA
Exciting CNS activity of #Checkmate9LA regimen presented by @DCarboneMD. Looking forward to the upcoming discussion by @CharuAggarwalMD vs Atezo-Brain study #WCLC21
#ASCO21 | #CheckMate9LA: with 2 years’ minimum follow-up, first-line NIVO + IPI + chemo demonstrated durable survival and benefit versus chemo in pts with advanced NSCLC; no new safety signals were identified. A comment by Diego Luigi Cortinovis.
#ASCO21 Day 1 #Lungcancer Abstracts Highlights
Abs 9000 Two-yr Survival update #Checkmate9LA, Ipi/Nivo+ 2 cycles chemo vs Standard Chemo
💥 mOS 15.8 vs 11 mos
💥 2yr OS 38% vs 26%
💥 ORR 38% vs 25%
➡️ No diff by PDL1 status
@MartinReck2 #lcsm @OncoAlert
Perhaps, before considering histology subgroups, we need to consider that #PDL1 could also be a prognostic factor as the #CheckMate9LA suggests for #NSCLC. Look at OS in less 1%(left), >1%(middle), >50%(right) with chemotherapy alone #ASCO21 @OncoAlert
Intriguing #Checkmate9LA results (wonderful presentation by @MartinReck2 btw) suggesting favourable OS in patients who discontinued treatment with nivolumab, ipilimumab and chemotherapy due to #TRAE #ASCO21 #LCSM @OncoAlert
Very nice article/summary @ASCOPost by Dr. Charu Aggarwal @CharuAggarwalMD on use of
Nivolumab/Ipilimumab + 2 cycles of chemo in 1st line Tx for metastatic #NSCLC
#CheckMate9LA
#CancerImmunotherapy #LCSM
Charu Aggarwal, MD, MPH, on Nivolumab/Ipilimumab Plus Two Cycles of Histology-Based Chemotherapy: Another Option in First-Line Metastatic NSCLC https://t.co/YRCad4QVHl #lcsm #oncology #cancer #immunotherapy @CharuAggarwalMD
Great to have recruited to this trial! Amazing HRs, impressive p values, esp good for those with no/low PDL1 expression. MS not reached in some subgroups of the Ix arm! #LCSM #Checkmate9LA @TheLancetOncol @LuisPaz_Ares @DrSanjayPopat
#OncoAlert Results from CheckMate 9LA now available @TheLancetOncol by @LuisPaz_Ares et al. Addition of nivolumab + ipilimumab to 2 cycles of chemotherapy in #NSCLC offered better OS than chemo alone (15.6m vs 10.9m, HR 0.66). Approved May 26, 2020. #LCSM
https://t.co/pHnRYM0HMl
European Approval granted for #nivolumab + #ipilimumab with two cycles of chemo for 1L #mNSCLC (all histologies, all PD-L1 expression) based on #CheckMate9LA (N+I+Chemo vs chemo):
✅OS: Reduced risk of death by 31% HR 0.66
✅mPFS 6.8m vs 5m HR 0.70
✅ORR 38% vs 25%
#immunotherapy
#ASCO20 | #CheckMate9LA: Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line (1L) treatment for stage IV/recurrent non-small cell lung cancer (#NSCLC). We asked Federico Cappuzzo a comment.
#ASCO20 | #CheckMate9LA: più efficace la combinazione nivolumab+ipilimumab+chemioterapia con platino doppietto rispetto a 4 cicli di chemioterapia nel trattamento del carcinoma polmonare non a piccole cellule in stadio IV/ricorrente.
https://t.co/noJ1syyfoQ
#ASCO20 | Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent #NSCLC. Francesco Grossi comments the study #CheckMate9LA.
#ASCO20 | Come armonizzare il trattamento in prima linea tra combinazione #nivolumab+#ipilimumab e chemioterapia nel #NSCLC? A questa domanda contribuiscono senza dubbio a rispondere i due trial #CheckMate227 Part 1 e #CheckMate9LA presentati all'@ASCO.
https://t.co/AbT8Z6Shs4
#ASCO20 #CheckMate9LA
Benefit is seen across all PDL1 subgroups and all histologic subtypes.
Proud to have participate this landmark study with @URCOT_lyon @CHUdeLyon
@OncoAlert
@FDAOncology approved nivolumab + ipilimumab & 2 cycles of platinum-doublet chemotherapy as 1st-line treatment for patients with metastatic/recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, approval was based on #CheckMate9LA summarized below: #lcsm #MedEd
Last Seen Hashtags on Sotwe
SatinOperaGloves
Seen from United States
金蹴り
Seen from United Kingdom
GVstar
Seen from Thailand
teenleaks
Seen from United States
trans
Seen from Indonesia
anxiouspanda
Seen from United States
DeğerÜretir
Seen from United States
bursatravesti
Seen from Turkey
minichat()********* filter:videos
Seen from United Kingdom
fit #skinny
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers